Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.

News and insights

Buildings

Publications: 18 July 2022

UPC – Adoption of the final Rules of Procedure

In our latest blogpost of 20 January 2022, we discussed the kick-off to the preparatory phase for the actual start of the Unified Patent Court (UPC). We are now one step closer to the actual start: on…

Read more
A businessman signing a contract

Publications: 14 March 2022

Podcast: Strategies when litigating divisional patents

Why are divisional patent applications important to consider when litigating a parent patent?

Read more
looking up at glass skyscrapers

Publications: 12 January 2022

The UK National Security and Investment Act 2021: the impact on M&A

The mergers and acquisitions (M&A) landscape in the UK changed on 4 January 2022 when the National Security and Investment Act 2021 (the Act) came fully into force. The following article has been…

Read more
shipping container and crane

Publications: 16 November 2021

The UK’s trade remedies regime

The creation of an independent UK trade remedies regime is a critical and under-reported aspect of the UK’s new trade policy. Going forward, the UK’s newfound ability to shape its own trade remedies…

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

Read more

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

UPC microsite

Ready for take-off

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

Our Life Sciences and Healthcare sector focus 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.